USPSTF: Aspirin Recommended for Some Aged 50 to 69 Years

Share this content:
USPSTF: Aspirin Recommended for Some Aged 50 to 69 Years
USPSTF: Aspirin Recommended for Some Aged 50 to 69 Years

MONDAY, April 11, 2016 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) recommends aspirin use for primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in certain adults aged 50 to 69 years, but not in younger or older adults. These findings form the basis of a recommendation statement, published online April 11 in the Annals of Internal Medicine.

Albert L. Siu, M.D., M.S.P.H., from the USPSTF, and colleagues reviewed the literature to update the 2009 recommendations relating to the combined benefits and harms of taking aspirin for primary prevention of both CVD events and CRC.

The researchers recommend low-dose aspirin for adults aged 50 to 59 years with a ≥10 percent 10-year CVD risk, without elevated bleeding risk, who have a ≥10 year life expectancy, and who are prepared to take aspirin daily for ≥10 years (B recommendation). For adults aged 60 to 69 years, the decision to initiate aspirin for primary prevention should be an individual one (C recommendation). The current evidence is insufficient to weigh the balance of benefits and harms of aspirin for primary prevention in adults aged younger than 50 years and age 70 years or older (I statements)

"Before starting to take aspirin for primary prevention, people aged 50 to 69 should talk to their primary care clinician to understand their risk of cardiovascular disease and risk for bleeding," USPSTF chair Kirsten Bibbins-Domingo, Ph.D., M.D., said in a statement.

Recommendation Statement
Evidence Review 1 (subscription or payment may be required)
Evidence Review 2 (subscription or payment may be required)
Decision Analysis (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »